ID   CSK22_HUMAN             Reviewed;         350 AA.
AC   P19784;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   12-APR-2017, entry version 184.
DE   RecName: Full=Casein kinase II subunit alpha';
DE            Short=CK II alpha';
DE            EC=2.7.11.1;
GN   Name=CSNK2A2; Synonyms=CK2A2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2174700; DOI=10.1021/bi00488a034;
RA   Lozeman F.J., Litchfield D.W., Piening C., Takio K., Walsh K.A.,
RA   Krebs E.G.;
RT   "Isolation and characterization of human cDNA clones encoding the
RT   alpha and the alpha' subunits of casein kinase II.";
RL   Biochemistry 29:8436-8447(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, AND INTERACTION WITH SSRP1 AND SUPT16H.
RX   PubMed=11239457; DOI=10.1016/S1097-2765(01)00176-9;
RA   Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H.,
RA   Goodman R., Lozano G., Zhao Y., Lu H.;
RT   "A DNA damage-induced p53 serine 392 kinase complex contains CK2,
RT   hSpt16, and SSRP1.";
RL   Mol. Cell 7:283-292(2001).
RN   [4]
RP   FUNCTION IN CELL CYCLE.
RX   PubMed=11704824; DOI=10.1038/sj.onc.1204894;
RA   Sayed M., Pelech S., Wong C., Marotta A., Salh B.;
RT   "Protein kinase CK2 is involved in G2 arrest and apoptosis following
RT   spindle damage in epithelial cells.";
RL   Oncogene 20:6994-7005(2001).
RN   [5]
RP   INTERACTION WITH SSRP1 AND SUPT16H.
RX   PubMed=12393879; DOI=10.1074/jbc.M209820200;
RA   Keller D.M., Lu H.;
RT   "p53 serine 392 phosphorylation increases after UV through induction
RT   of the assembly of the CK2.hSPT16.SSRP1 complex.";
RL   J. Biol. Chem. 277:50206-50213(2002).
RN   [6]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=16193064; DOI=10.1038/sj.emboj.7600827;
RA   Shin S., Lee Y., Kim W., Ko H., Choi H., Kim K.;
RT   "Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by
RT   processing procaspase-8.";
RL   EMBO J. 24:3532-3542(2005).
RN   [7]
RP   REVIEW ON FUNCTION.
RX   PubMed=12631575; DOI=10.1096/fj.02-0473rev;
RA   Meggio F., Pinna L.A.;
RT   "One-thousand-and-one substrates of protein kinase CK2?";
RL   FASEB J. 17:349-368(2003).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18; SER-21 AND SER-288,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   REVIEW ON STRUCTURE.
RX   PubMed=19387553; DOI=10.1007/s00018-009-9149-8;
RA   Niefind K., Raaf J., Issinger O.G.;
RT   "Protein kinase CK2 in health and disease: Protein kinase CK2: from
RT   structures to insights.";
RL   Cell. Mol. Life Sci. 66:1800-1816(2009).
RN   [10]
RP   REVIEW ON FUNCTION.
RX   PubMed=19387552; DOI=10.1007/s00018-009-9150-2;
RA   St-Denis N.A., Litchfield D.W.;
RT   "Protein kinase CK2 in health and disease: From birth to death: the
RT   role of protein kinase CK2 in the regulation of cell proliferation and
RT   survival.";
RL   Cell. Mol. Life Sci. 66:1817-1829(2009).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=19387551; DOI=10.1007/s00018-009-9151-1;
RA   Filhol O., Cochet C.;
RT   "Protein kinase CK2 in health and disease: Cellular functions of
RT   protein kinase CK2: a dynamic affair.";
RL   Cell. Mol. Life Sci. 66:1830-1839(2009).
RN   [12]
RP   REVIEW ON FUNCTION IN REGULATION OF HSP90.
RX   PubMed=19387550; DOI=10.1007/s00018-009-9152-0;
RA   Miyata Y.;
RT   "Protein kinase CK2 in health and disease: CK2: the kinase controlling
RT   the Hsp90 chaperone machinery.";
RL   Cell. Mol. Life Sci. 66:1840-1849(2009).
RN   [13]
RP   REVIEW ON FUNCTION IN WNT SIGNALING.
RX   PubMed=19387549; DOI=10.1007/s00018-009-9153-z;
RA   Dominguez I., Sonenshein G.E., Seldin D.C.;
RT   "Protein kinase CK2 in health and disease: CK2 and its role in Wnt and
RT   NF-kappaB signaling: linking development and cancer.";
RL   Cell. Mol. Life Sci. 66:1850-1857(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-13; SER-18; SER-21 AND
RP   SER-288, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-97, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 1-334 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=19193990; DOI=10.1107/S1744309108043194;
RA   Nakaniwa T., Kinoshita T., Sekiguchi Y., Tada T., Nakanishi I.,
RA   Kitaura K., Suzuki Y., Ohno H., Hirasawa A., Tsujimoto G.;
RT   "Structure of human protein kinase CK2 alpha 2 with a potent indazole-
RT   derivative inhibitor.";
RL   Acta Crystallogr. F 65:75-79(2009).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS).
RX   PubMed=21241709; DOI=10.1016/j.jmb.2011.01.020;
RA   Bischoff N., Olsen B., Raaf J., Bretner M., Issinger O.G., Niefind K.;
RT   "Structure of the human protein kinase CK2 catalytic subunit CK2alpha'
RT   and interaction thermodynamics with the regulatory subunit CK2beta.";
RL   J. Mol. Biol. 407:1-12(2011).
RN   [20]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-188.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Catalytic subunit of a constitutively active
CC       serine/threonine-protein kinase complex that phosphorylates a
CC       large number of substrates containing acidic residues C-terminal
CC       to the phosphorylated serine or threonine. Regulates numerous
CC       cellular processes, such as cell cycle progression, apoptosis and
CC       transcription, as well as viral infection. May act as a regulatory
CC       node which integrates and coordinates numerous signals leading to
CC       an appropriate cellular response. During mitosis, functions as a
CC       component of the p53/TP53-dependent spindle assembly checkpoint
CC       (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in
CC       response to spindle damage. Also required for p53/TP53-mediated
CC       apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV
CC       irradiation. Can also negatively regulate apoptosis.
CC       Phosphorylates the caspases CASP9 and CASP2 and the apoptotic
CC       regulator NOL3. Phosphorylation protects CASP9 from cleavage and
CC       activation by CASP8, and inhibits the dimerization of CASP2 and
CC       activation of CASP8. Regulates transcription by direct
CC       phosphorylation of RNA polymerases I, II, III and IV. Also
CC       phosphorylates and regulates numerous transcription factors
CC       including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX,
CC       JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones
CC       FKBP4 and CDC37, which is essential for chaperone function.
CC       Regulates Wnt signaling by phosphorylating CTNNB1 and the
CC       transcription factor LEF1. Acts as an ectokinase that
CC       phosphorylates several extracellular proteins. During viral
CC       infection, phosphorylates various proteins involved in the viral
CC       life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV.
CC       {ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11704824,
CC       ECO:0000269|PubMed:16193064}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Constitutively active protein kinase whose
CC       activity is not directly affected by phosphorylation. Seems to be
CC       regulated by level of expression and localization (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Heterotetramer composed of two catalytic subunits (alpha
CC       chain and/or alpha' chain) and two regulatory subunits (beta
CC       chains). The tetramer can exist as a combination of 2 alpha/2
CC       beta, 2 alpha'/2 beta or 1 alpha/1 alpha'/2 beta subunits. Also
CC       part of a CK2-SPT16-SSRP1 complex composed of SSRP1, SUPT16H,
CC       CSNK2A1, CSNK2A2 and CSNK2B, which forms following UV irradiation.
CC       Interacts with RNPS1. {ECO:0000269|PubMed:11239457,
CC       ECO:0000269|PubMed:12393879, ECO:0000269|PubMed:19193990}.
CC   -!- INTERACTION:
CC       P68400:CSNK2A1; NbExp=6; IntAct=EBI-347451, EBI-347804;
CC       P67870:CSNK2B; NbExp=8; IntAct=EBI-347451, EBI-348169;
CC       O60282:KIF5C; NbExp=4; IntAct=EBI-347451, EBI-717170;
CC       Q8WV44:TRIM41; NbExp=5; IntAct=EBI-347451, EBI-725997;
CC   -!- MISCELLANEOUS: Can use both ATP and GTP as phosphoryl donors.
CC       Phosphorylation by casein kinase 2 has been estimated to represent
CC       up to one quarter of the eukaryotic phosphoproteome.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. CK2 subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M55268; AAA51548.1; -; mRNA.
DR   EMBL; BC008812; AAH08812.1; -; mRNA.
DR   CCDS; CCDS10794.1; -.
DR   PIR; B35838; B35838.
DR   RefSeq; NP_001887.1; NM_001896.2.
DR   UniGene; Hs.82201; -.
DR   PDB; 3E3B; X-ray; 3.20 A; X=1-334.
DR   PDB; 3OFM; X-ray; 2.00 A; A=1-350.
DR   PDB; 3U87; X-ray; 2.90 A; A/B=327-350.
DR   PDB; 5M4U; X-ray; 2.19 A; A=1-350.
DR   PDB; 5M56; X-ray; 2.24 A; A/B=1-350.
DR   PDBsum; 3E3B; -.
DR   PDBsum; 3OFM; -.
DR   PDBsum; 3U87; -.
DR   PDBsum; 5M4U; -.
DR   PDBsum; 5M56; -.
DR   ProteinModelPortal; P19784; -.
DR   SMR; P19784; -.
DR   BioGrid; 107842; 213.
DR   DIP; DIP-318N; -.
DR   IntAct; P19784; 151.
DR   MINT; MINT-5004107; -.
DR   STRING; 9606.ENSP00000262506; -.
DR   BindingDB; P19784; -.
DR   ChEMBL; CHEMBL4070; -.
DR   DrugBank; DB07546; [1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid.
DR   GuidetoPHARMACOLOGY; 1550; -.
DR   iPTMnet; P19784; -.
DR   PhosphoSitePlus; P19784; -.
DR   BioMuta; CSNK2A2; -.
DR   DMDM; 125266; -.
DR   SWISS-2DPAGE; P19784; -.
DR   EPD; P19784; -.
DR   MaxQB; P19784; -.
DR   PaxDb; P19784; -.
DR   PeptideAtlas; P19784; -.
DR   PRIDE; P19784; -.
DR   DNASU; 1459; -.
DR   Ensembl; ENST00000262506; ENSP00000262506; ENSG00000070770.
DR   GeneID; 1459; -.
DR   KEGG; hsa:1459; -.
DR   UCSC; uc002enc.4; human.
DR   CTD; 1459; -.
DR   DisGeNET; 1459; -.
DR   GeneCards; CSNK2A2; -.
DR   HGNC; HGNC:2459; CSNK2A2.
DR   HPA; HPA077719; -.
DR   MIM; 115442; gene.
DR   neXtProt; NX_P19784; -.
DR   OpenTargets; ENSG00000070770; -.
DR   PharmGKB; PA26959; -.
DR   eggNOG; KOG0668; Eukaryota.
DR   eggNOG; ENOG410XNPP; LUCA.
DR   GeneTree; ENSGT00390000004215; -.
DR   HOGENOM; HOG000233021; -.
DR   HOVERGEN; HBG107282; -.
DR   KO; K03097; -.
DR   OMA; NREYWDY; -.
DR   OrthoDB; EOG091G0AZY; -.
DR   PhylomeDB; P19784; -.
DR   TreeFam; TF300483; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-1483191; Synthesis of PC.
DR   Reactome; R-HSA-201688; WNT mediated activation of DVL.
DR   Reactome; R-HSA-2514853; Condensation of Prometaphase Chromosomes.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6814122; Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding.
DR   SignaLink; P19784; -.
DR   SIGNOR; P19784; -.
DR   ChiTaRS; CSNK2A2; human.
DR   EvolutionaryTrace; P19784; -.
DR   GeneWiki; CSNK2A2; -.
DR   GenomeRNAi; 1459; -.
DR   PRO; PR:P19784; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000070770; -.
DR   CleanEx; HS_CSNK2A2; -.
DR   ExpressionAtlas; P19784; baseline and differential.
DR   Genevisible; P19784; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:0071174; P:mitotic spindle checkpoint; IMP:UniProtKB.
DR   GO; GO:0006656; P:phosphatidylcholine biosynthetic process; TAS:Reactome.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006457; P:protein folding; TAS:Reactome.
DR   GO; GO:1903146; P:regulation of mitophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Cell cycle;
KW   Complete proteome; Kinase; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transcription; Transcription regulation; Transferase;
KW   Wnt signaling pathway.
FT   CHAIN         1    350       Casein kinase II subunit alpha'.
FT                                /FTId=PRO_0000085891.
FT   DOMAIN       40    325       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      46     54       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    157    157       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      69     69       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      13     13       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES      18     18       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES      97     97       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     288    288       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   VARIANT     188    188       E -> A (in dbSNP:rs55911801).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040416.
FT   STRAND       11     13       {ECO:0000244|PDB:3OFM}.
FT   TURN         14     16       {ECO:0000244|PDB:3OFM}.
FT   HELIX        17     19       {ECO:0000244|PDB:3OFM}.
FT   HELIX        22     25       {ECO:0000244|PDB:3OFM}.
FT   HELIX        27     29       {ECO:0000244|PDB:3OFM}.
FT   HELIX        37     39       {ECO:0000244|PDB:3OFM}.
FT   STRAND       40     48       {ECO:0000244|PDB:3OFM}.
FT   STRAND       50     59       {ECO:0000244|PDB:3OFM}.
FT   TURN         60     63       {ECO:0000244|PDB:3OFM}.
FT   STRAND       64     71       {ECO:0000244|PDB:3OFM}.
FT   HELIX        76     88       {ECO:0000244|PDB:3OFM}.
FT   TURN         89     91       {ECO:0000244|PDB:3OFM}.
FT   STRAND       98    103       {ECO:0000244|PDB:3OFM}.
FT   TURN        105    107       {ECO:0000244|PDB:3OFM}.
FT   STRAND      110    115       {ECO:0000244|PDB:3OFM}.
FT   HELIX       122    125       {ECO:0000244|PDB:3OFM}.
FT   TURN        126    128       {ECO:0000244|PDB:5M56}.
FT   HELIX       131    150       {ECO:0000244|PDB:3OFM}.
FT   HELIX       160    162       {ECO:0000244|PDB:3OFM}.
FT   STRAND      163    166       {ECO:0000244|PDB:3OFM}.
FT   TURN        167    170       {ECO:0000244|PDB:3OFM}.
FT   STRAND      171    174       {ECO:0000244|PDB:3OFM}.
FT   HELIX       196    198       {ECO:0000244|PDB:3OFM}.
FT   HELIX       201    204       {ECO:0000244|PDB:3OFM}.
FT   HELIX       213    228       {ECO:0000244|PDB:3OFM}.
FT   STRAND      231    234       {ECO:0000244|PDB:3OFM}.
FT   HELIX       239    250       {ECO:0000244|PDB:3OFM}.
FT   HELIX       252    261       {ECO:0000244|PDB:3OFM}.
FT   HELIX       270    273       {ECO:0000244|PDB:3OFM}.
FT   HELIX       282    285       {ECO:0000244|PDB:3OFM}.
FT   TURN        288    290       {ECO:0000244|PDB:3OFM}.
FT   HELIX       291    293       {ECO:0000244|PDB:3OFM}.
FT   HELIX       296    305       {ECO:0000244|PDB:3OFM}.
FT   TURN        310    312       {ECO:0000244|PDB:3OFM}.
FT   HELIX       316    320       {ECO:0000244|PDB:3OFM}.
FT   HELIX       323    325       {ECO:0000244|PDB:3OFM}.
FT   HELIX       326    331       {ECO:0000244|PDB:3OFM}.
SQ   SEQUENCE   350 AA;  41213 MW;  3ECB92F6BD3DD7F1 CRC64;
     MPGPAAGSRA RVYAEVNSLR SREYWDYEAH VPSWGNQDDY QLVRKLGRGK YSEVFEAINI
     TNNERVVVKI LKPVKKKKIK REVKILENLR GGTNIIKLID TVKDPVSKTP ALVFEYINNT
     DFKQLYQILT DFDIRFYMYE LLKALDYCHS KGIMHRDVKP HNVMIDHQQK KLRLIDWGLA
     EFYHPAQEYN VRVASRYFKG PELLVDYQMY DYSLDMWSLG CMLASMIFRR EPFFHGQDNY
     DQLVRIAKVL GTEELYGYLK KYHIDLDPHF NDILGQHSRK RWENFIHSEN RHLVSPEALD
     LLDKLLRYDH QQRLTAKEAM EHPYFYPVVK EQSQPCADNA VLSSGLTAAR
//
